Personalis reports Q1 EPS (26c), consensus (41c)

Reports Q1 revenue $19.525M, consensus $18.36M. “We began 2024 with strong execution as we delivered revenue of $19.5 million in the first quarter, exceeding the upper-end of our guidance range, and we continue to develop compelling NeXT Personal clinical evidence as we work towards obtaining Medicare coverage,” said Chris Hall, Chief Executive Officer. “Our efforts in 2024 are focused on executing on the four pillars of our Win-in-MRD strategy: focusing on cancer types where we believe our test provides the most value, generating robust clinical evidence with top KOLs to support our submission for Medicare coverage, leveraging our early success with biopharma customers to accelerate adoption, and working with Tempus AI to expedite commercialization in a capital-efficient manner.”